Larimar Therapeutics Inc (LRMR)

9.67 +0.29  +3.09% NASDAQ Dec 7, 14:08 USD
View Full Chart
Price Chart
View All LRMR News

News

View All Events

Events

Date Type Description
03/04/2022 Earnings Results Q4 2021 Earnings Results
11/12/2021 Earnings Results Q3 2021 Earnings Results
08/12/2021 Earnings Results Q2 2021 Earnings Results
05/12/2021 10:00 EST AGM 2020 Annual General Meeting
05/10/2021 Earnings Results Q1 2021 Earnings Results
03/04/2021 Earnings Results Q4 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
  • URL: https://www.larimartx.com
  • Investor Relations URL: https://investors.larimartx.com/
  • HQ State/Province: Pennsylvania
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: N/A
  • Next Earnings Release: Mar. 04, 2022
  • Last Earnings Release: Nov. 12, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.